Ide Toshihiro, Kawanami Takeru, Eriguchi Makoto, Hara Hideo
Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine, Japan.
Intern Med. 2022 Apr 15;61(8):1253-1258. doi: 10.2169/internalmedicine.8709-21. Epub 2022 Feb 8.
We herein report a case of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 24-year-old woman developed unilateral optic neuritis 3 weeks after contracting coronavirus disease 2019 (COVID-19), followed by intracranial demyelinating lesions and myelitis. Since serum anti-MOG antibody was positive, we diagnosed MOG antibody-associated disease. Immunotherapy with steroids resulted in the rapid improvement of neurological symptoms. This is a suggestive case, as there are no reports of MOG antibody-associated disease with multiple neurological lesions occurring after COVID-19. The response to immunotherapy was favorable. This case suggests that it is important to measure anti-MOG antibodies in patients who develop inflammatory neurological disease after COVID-19.
我们在此报告一例严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染后发生的髓鞘少突胶质细胞糖蛋白(MOG)抗体相关疾病。一名24岁女性在感染2019冠状病毒病(COVID-19)3周后出现单侧视神经炎,随后出现颅内脱髓鞘病变和脊髓炎。由于血清抗MOG抗体呈阳性,我们诊断为MOG抗体相关疾病。使用类固醇进行免疫治疗使神经症状迅速改善。这是一个具有提示意义的病例,因为尚无COVID-19后发生伴有多种神经病变的MOG抗体相关疾病的报告。免疫治疗反应良好。该病例表明,对COVID-19后发生炎性神经疾病的患者检测抗MOG抗体很重要。